<DOC>
	<DOCNO>NCT00000975</DOCNO>
	<brief_summary>To evaluate feasibility itraconazole ( 1 ) primary therapy histoplasmosis ( 2 ) maintenance therapy completion primary therapy . To evaluate effect therapy CNS histoplasmosis . To determine resistance drug occur patient fail therapy . Histoplasmosis serious opportunistic infection patient AIDS . Although clinical response amphotericin B treatment AIDS patient generally good , administration difficulty toxicity detract usefulness . Oral treatment ketoconazole overcomes limitation amphotericin B , appear effective primary treatment patient AIDS . Itraconazole triazole compound preclinical study demonstrate activity Histoplasmosis capsulatum . Preclinical study also show itraconazole appear effective treatment histoplasmosis . The frequency adverse reaction itraconazole low several study . Central nervous system ( CNS ) involvement occur 20 percent patient histoplasmosis , appear poor response amphotericin B treatment . Itraconazole use successfully small number patient cryptococcal meningitis , support study use CNS histoplasmosis .</brief_summary>
	<brief_title>A Study Itraconazole Treatment Prevention Histoplasmosis , Fungal Infection , Patients With AIDS</brief_title>
	<detailed_description>Histoplasmosis serious opportunistic infection patient AIDS . Although clinical response amphotericin B treatment AIDS patient generally good , administration difficulty toxicity detract usefulness . Oral treatment ketoconazole overcomes limitation amphotericin B , appear effective primary treatment patient AIDS . Itraconazole triazole compound preclinical study demonstrate activity Histoplasmosis capsulatum . Preclinical study also show itraconazole appear effective treatment histoplasmosis . The frequency adverse reaction itraconazole low several study . Central nervous system ( CNS ) involvement occur 20 percent patient histoplasmosis , appear poor response amphotericin B treatment . Itraconazole use successfully small number patient cryptococcal meningitis , support study use CNS histoplasmosis . At least 30 patient AIDS initial episode disseminate histoplasmosis select study . Up 5 patient diagnosis CNS histoplasmosis . Therapy systemic antifungal agent must halt study entry . Patients receive itraconazole 3 day follow daily oral dos total 12 week . Patients well clinically , without evidence clinical failure dose-limiting toxicity , permit continue maintenance therapy prevent relapse reduce dose additional 12 month . Patients treat CNS histoplasmosis continue receive itraconazole .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Histoplasmosis</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Vincristine , vinblastine , bleomycin , interferon Kaposi 's sarcoma . Erythropoietin . Didanosine exemption 10 patient . Barbiturates . Coumarintype anticoagulant . Oral contraceptive . Digoxin . Methadone . Narcotics . Acyclovir . Acetaminophen . Sulfonamides . Trimethoprim / sulfamethoxazole . Pentamidine Pneumocystis carinii pneumonia ( PCP ) PCP prophylaxis . Topical antifungal . Pyrimethamine . Ganciclovir . AZT . Stress dose steroid patient adrenal insufficiency . Concurrent Treatment : Allowed : Dose reduction interruption myelosuppressive therapy transfusion maintain hemoglobin 7 g/dl . Radiation therapy . Patient must : Show laboratory evidence HIV infection disseminate histoplasmosis . Be orient person , place , time . Be able give write informed consent ( appropriate consent must obtain parent legal guardian patient 18 year age ) . Allowed : Abnormal liver function test Grade 3 toxicity range liver biopsy show evidence histoplasmosis cause abnormality . Mucocutaneous candidiasis . Prior Medication : Allowed : Amphotericin B ketoconazole pulmonary histoplasmosis least 3 month prior study entry . Azidothymidine ( AZT ) . Vincristine , vinblastine , bleomycin , interferon mucocutaneous Kaposi 's sarcoma . Prophylaxis Pneumocystis carinii pneumonia ( PCP ) . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Severely ill , risk die histoplasmosis within first week treatment , indicate systolic blood pressure le 90 mm Hg , PO2 le 60 . Active CNS lesion , malignancy , infection MAI . Severe malabsorption syndrome ( persistent diarrhea 4 week duration least 4 loose stool per day accompany 10 percent great weight loss ) . Requiring cytotoxic therapy malignancy . Any systemic fungal infection histoplasmosis . Systemic Mycobacterium avium intracellulare . Receiving treatment acute opportunistic infection whose sign symptoms yet resolve stabilize . History allergy intolerance imidazole azoles . Concurrent Medication : Excluded : All systemic antifungal agent . Investigational drug specifically allow . Oral hypoglycemics . Rifamycins . Phenytoin . Carbamazepine . Steroids excess physiologic replacement dos specifically allow . Cytotoxic chemotherapy . Discouraged : Antacids . Sucralfate . H2 blocker . Patients follow exclude : Severely ill , risk die histoplasmosis within first week treatment . Active CNS infection , malignancy lesion document caused histoplasmosis , would interfere assessment response . Unable take oral medication reliably . Severe malabsorption syndrome . Requiring cytotoxic therapy malignancy . Any systemic fungal infection histoplasmosis . Systemic Mycobacterium avium intracellulare . Receiving treatment acute opportunistic infection whose sign symptoms yet resolve stabilize . Prior Medication : Excluded great 1 week within last 3 month : Fluconazole . Itraconazole . SCH 39304 . Amphotericin B great 1.5 mg/kg , antifungal episode disseminate histoplasmosis . Patients investigator feel would undependable regard adherence protocol .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Histoplasmosis</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Antifungal Agents</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>